183 related articles for article (PubMed ID: 27080571)
21. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
[TBL] [Abstract][Full Text] [Related]
22. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
[TBL] [Abstract][Full Text] [Related]
23. Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.
Bahmani B; Uehara M; Ordikhani F; Li X; Jiang L; Banouni N; Ichimura T; Kasinath V; Eskandari SK; Annabi N; Bromberg JS; Shultz LD; Greiner DL; Abdi R
EBioMedicine; 2018 Dec; 38():79-88. PubMed ID: 30497977
[TBL] [Abstract][Full Text] [Related]
24. Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance.
Wang L; Liu X; Zhou Q; Sui M; Lu Z; Zhou Z; Tang J; Miao Y; Zheng M; Wang W; Shen Y
Biomaterials; 2017 Nov; 144():105-118. PubMed ID: 28837958
[TBL] [Abstract][Full Text] [Related]
25. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
26. Quantitative magnetization transfer MRI of desmoplasia in pancreatic ductal adenocarcinoma xenografts.
Li W; Zhang Z; Nicolai J; Yang GY; Omary RA; Larson AC
NMR Biomed; 2013 Dec; 26(12):1688-95. PubMed ID: 23940016
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.
Hollevoet K; Mason-Osann E; Liu XF; Imhof-Jung S; Niederfellner G; Pastan I
Mol Cancer Ther; 2014 Aug; 13(8):2040-9. PubMed ID: 24928849
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
29. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis.
Yamahatsu K; Matsuda Y; Ishiwata T; Uchida E; Naito Z
Int J Oncol; 2012 May; 40(5):1345-57. PubMed ID: 22246533
[TBL] [Abstract][Full Text] [Related]
30. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
31. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
[TBL] [Abstract][Full Text] [Related]
32. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.
Sharma NS; Gupta VK; Garrido VT; Hadad R; Durden BC; Kesh K; Giri B; Ferrantella A; Dudeja V; Saluja A; Banerjee S
J Clin Invest; 2020 Jan; 130(1):451-465. PubMed ID: 31613799
[TBL] [Abstract][Full Text] [Related]
33. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer.
Kang M; Jiang B; Xu B; Lu W; Guo Q; Xie Q; Zhang B; Dong X; Chen D; Wu Y
Cancer Lett; 2013 Mar; 330(1):11-21. PubMed ID: 23200678
[TBL] [Abstract][Full Text] [Related]
34. Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
Chen X; Yu Q; Liu Y; Sheng Q; Shi K; Wang Y; Li M; Zhang Z; He Q
Acta Biomater; 2019 Nov; 99():339-349. PubMed ID: 31499197
[TBL] [Abstract][Full Text] [Related]
35. Mouse Models of Pancreatic Ductal Adenocarcinoma.
Ponz-Sarvise M; Tuveson DA; Yu KH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
[TBL] [Abstract][Full Text] [Related]
36. Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line.
Yanagihara K; Kubo T; Mihara K; Kuwata T; Ochiai A; Seyama T; Yokozaki H
Pancreas; 2019 Mar; 48(3):315-322. PubMed ID: 30747829
[TBL] [Abstract][Full Text] [Related]
37. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy.
Oyama Y; Onishi H; Koga S; Murahashi M; Ichimiya S; Nakayama K; Fujimura A; Kawamoto M; Imaizumi A; Umebayashi M; Ohuchida K; Morisaki T; Nakamura M
J Immunother; 2020 May; 43(4):121-133. PubMed ID: 31834207
[TBL] [Abstract][Full Text] [Related]
38. Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model.
Bressand D; Novell A; Girault A; Raoul W; Fromont-Hankard G; Escoffre JM; Lecomte T; Bouakaz A
Mol Pharm; 2019 Sep; 16(9):3814-3822. PubMed ID: 31356090
[TBL] [Abstract][Full Text] [Related]
39. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
[TBL] [Abstract][Full Text] [Related]
40. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
